New drug combo tested for Tough-to-Treat uterine cancer
NCT ID NCT02755844
Summary
This study tested the safety and effectiveness of a combination of three existing drugs—olaparib, cyclophosphamide, and metformin—for women with recurrent or advanced endometrial (uterine) cancer that had stopped responding to standard chemotherapy. The main goals were to find the safest dose and see if the combination could stop the cancer from growing. The trial involved 35 participants and was an early-stage study to gather initial evidence.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Comité Gynécologique, Institut Gustave Roussy
Villejuif, 94800, France
-
Département d'Oncologie Médicale, Centre Antoine Lacassagne
Nice, 06189, France
-
Département de Cancérologie Cervico-Faciale et Thoracique, Centre Oscar Lambret
Lille, 59000, France
-
Service d'Oncologie Médicale, Centre François Baclesse
Caen, 14076, France
-
Service d'Oncologie Médicale, Institut Curie
Paris, 75248, France
Conditions
Explore the condition pages connected to this study.